April 8, 2021

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): vaccination, variants

• A single dose of the Pfizer-BioNTech vaccine substantially increased neutralizing activity against SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1 among healthcare workers (HCWs) previously infected with SARS-CoV-2 (n=6). Serum samples from each HCW were obtained 1-12 weeks after natural infection, immediately before vaccination, and 1-2 weeks after vaccination and were tested using a microneutralization assay containing isolates of the parent strain and SARS-CoV-2 variants. Geometric mean titers (GMTs) for neutralizing activity were low prior to vaccination against the parent strain, B.1.1.7, P.1, and B.1.351 variants (GMTs: 81, 40, 36, and 7, respectively), but increased by 114-, 203-, 81-, and 228-fold after vaccination, respectively (corresponding GMTs: 9195, 8192, 2896, and 1625).

Lustig et al. (Apr 7, 2021). Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2. New England Journal of Medicine. https://doi.org/10.1056/NEJMc2104036